Loading
IARC estimates 25,125 new cancer cases and 16,378 cancer deaths in Zimbabwe in 2024; the commonest new cancers are cervix uteri, prostate and breast. This page is assembled automatically from OnCo's data: 1 trial with a site there, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Cervix uteri | 5,194 | 89.5 | Cervical cancer |
| Prostate | 3,635 | 113.5 | Prostate cancer |
| Breast | 2,483 | 42.4 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Oesophagus | 1,412 | 16.8 | Oesophageal cancer |
| Colorectum | 1,375 | 15.3 | Colorectal cancer |
| Stomach | 1,042 | 12.3 | Gastric & gastro-oesophageal junction cancer |
| Non-Hodgkin lymphoma | 890 | 8.0 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Liver and intrahepatic bile ducts | 842 | 9.1 | Hepatocellular carcinoma |
| Trachea, bronchus and lung | 783 | 9.3 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Kaposi sarcoma | 551 | 4.5 | Kaposi sarcoma |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Cervix uteri | 3,118 | 54.9 | Cervical cancer |
| Prostate | 2,298 | 71.4 | Prostate cancer |
| Oesophagus | 1,283 | 15.5 | Oesophageal cancer |
| Breast | 1,224 | 21.8 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Stomach | 881 | 10.7 | Gastric & gastro-oesophageal junction cancer |
| Colorectum | 797 | 9.3 | Colorectal cancer |
| Liver and intrahepatic bile ducts | 766 | 8.4 | Hepatocellular carcinoma |
| Trachea, bronchus and lung | 726 | 8.7 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Non-Hodgkin lymphoma | 453 | 4.4 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Pancreas | 433 | 5.1 | Pancreatic ductal adenocarcinoma |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
ACTG A5263/AMC 066 NCT01435018 | Phase 3 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 11 | 2021-10-20 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Zimbabwe, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Zimbabwe is open is on the registry page, under Contacts and Locations.
OnCo holds no institution, company or person in Zimbabwe.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Zimbabwe is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
A deep dive for Zimbabwe is ranked 58 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.